CNVVF (Convatec Group) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CNVVF Convatec Group PLC CNVVF
78 GF Score
Price $2.95
GF Value $3.09
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Convatec Group FFO?

FFO (Funds from operations) only applies to REITs.

CNVVF
78GF Score
Convatec Group PLC CNVVF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Convatec Group (CNVVF) Overvalued in 2026?

Based on GuruFocus' analysis, Convatec Group stock appears to be undervalued. The current stock price of $2.95 is trading 4.5% below its estimated GF Value™ of $3.09. GuruFocus considers Convatec Group to be Fairly Valued.

Key valuation signals for CNVVF:

  • FFO:
  • GF Value™: $3.09 vs. price of $2.95 (4.5% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the CNVVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Convatec Group Business Description

Address 20 Eastbourne Terrace, 7th Floor, London, GBR, W2 6LG
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
78GF Score

Get the complete analysis for CNVVF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.95
Price
$3.09
GF Value